{
  "chunk_id": "V_iii_7_None_27",
  "content": "/>\nV.iii.7.3.a\n.\nBPH\nBenign prostatic hypertrophy (BPH) is evaluated under\n38 CFR 4.115b, DC 7527\nbased on associated voiding dysfunction or urinary tract infection, but can be evaluated as renal dysfunction when applicable.  Consider the following when rating BPH:\nBPH and some types of treatment for BPH, such as alpha blocker drugs, finasteride, or balloon dilation, can cause incontinence.\nRetrograde ejaculation can result from some types of BPH treatment, especially transurethral resection of the prostate (TURP).\nSpecial monthly compensation (SMC) (k) may be warranted if there is associated erectile dysfunction (\nED)\nor retrograde ejaculation as a result of treatment or if hormone therapy is used.  SMC entitlement is determined on a factual basis.",
  "title": "M21-1, Part V, Subpart iii, Chapter 7 - Genitourinary Disabilities",
  "citation": "Part V, Subpart iii, Chapter 7, Section None",
  "source_url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180593/M21-1-Part-V-Subpart-iii-Chapter-7-Genitourinary-Disabilities",
  "updated": "",
  "scraped_at": "2025-06-16T22:45:07.512056",
  "tags": [
    "m21-1"
  ]
}